Interview: Vertex CEO worries about 'hyper-focus' on hep C

No question that Vertex Pharmaceuticals ($VRTX) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who takes over for Matthew Emmens Feb. 1. FierceBiotech chatted with both men about the challenges. Interview

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.